CHANGSHA, China, August 4, 2021 / PRNewswire / – Recently, Micomme joined with Polish and Peruvian partners for accomplish the government centralized purchase 1,600 and 1,500 units of HFNC, respectively. Both purchases are strategic material reserves of the Governments. The global pandemic is still In progress, and the safety of people’s lives is the main objective pursued by governments. The projects also reflect the foresight and determination of local actors Governments. The two purchases were delivered in June 2021.
As a leader in non-invasive respiratory therapy in China, Micome Medical launched its first transnasal high flow nasal cannula oxygen therapy device (hereafter referred to as HFNC) OH-70C in 2017. At the start of the epidemic, Micomme Medical reacted quickly to the traditional Chinese Spring Festival. All employees have returned to work after the holidays, the production line has been fully activated and more than 5,000 units of HFNC were sent to Wuhan immediately. In 2020, As reached more than 10,000 HFNC installations worldwide (China not included), and help countries around the world are battling COVID-19 with a production capacity of 500 units per day.
The Transnasal High Flow Nasal Cannula Oxygen Therapy Device is the machine recommended by WHO and related international guidelines for the treatment of patients with COVID-19. It aims to rapidly increase patient oxygen saturation (SpO2) and improve symptoms of hypoxia in patients by providing high flow air-oxygen gas mixture to patients with constant temperature, humidity and oxygen concentration. . As one of the first manufacturers of HFNC in China, Micomme has won the market recognition with its excellent product quality and brilliant product performance. In the fight against COVID-19, Micomme fulfills his commitment as a leader company.
For more details, please contact: [email protected]